Martínez-Ramos D, Escrig-Sos J, García-Redón T, Fortea-Sanchis C, Alcalde-Sánchez M, Salvador-Sanchis JL

Language: Spanish
References: 21
Page: 402-408
PDF size: 504.85 Kb.

ABSTRACT

Background: Breast screening programs in Spain cover almost 100% of population. The objective of the present study was to analyze if there have been any changes during the last decade in our breast screening unit that can also be extrapolated to other breast screening units.
Methods: We conducted a retrospective and descriptive analysis reviewing patients seen in our breast screening unit between January 1, 2000 and December 31, 2009. Patients with a final diagnosis of carcinoma, year of diagnosis, age, histological type, infiltration, surgical procedure and tumor extension were analyzed.
Results: A total of 311 breast cancers were diagnosed among 90,010 women who were seen at our breast screening unit. Mean age of the patients was 56 years. A progressive increase of the target population was seen (24,004 persons in 2000 and 31,950 in 2009). Histological type, percentage of infiltrative tumors and lymph node involvement did not show significant differences by year. Differences were observed for tumor size (pT category of TNM classification) and conservative surgery.
Conclusions: Tumor stage in cancers diagnosed in breast screening units progressively decreases when the program is being implemented. There is a maximum level among which tumor characteristics remain constant. Changes in screening programs can modify these characteristics.

REFERENCES

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-488.

2. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001;358:1340-1342.

3. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2009 Oct 7;(4): CD001877. DOI: 10.1002/14651858.CD001877.pub3.

4. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-1792.

5. Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr 2006;36:7-15.

6. Vidal-Lancis C, Martínez-Sánchez JM, Mateos-Mazón M, Peris- Tuser M. Mortalidad por cáncer de mama: evolución en España y sus comunidades autónomas durante el período 1980-2005. Rev Esp Salud Publica 2010;84:53-59.

7. Pollán M, Michelena MJ, Ardanaz E, Izquierdo A, Sánchez-Pérez MJ, Torrella A, et al. Breast cancer incidence in Spain before, during and after the implementation of screening programmes. Ann Oncol 2010;21(Suppl 3):iii97-iii102.

8. Tyczynski JE, Demarét E, Parkin DM. Standards and Guidelines for Cancer Registration in Europe. The ENCR Recommendations. Vol. I. IARC Technical Publication No. 40. Lyon, France: IARC; 2003.

9. Martínez-Ramos D, García-Redó T, Escrig J, Alcalde M, Rivadulla MI, Daroca JM, et al. Cambios en el estadio evolutivo en el momento del diagnóstico tras 10 años de cribado poblacional de cáncer de mama. Rev Senologia Patol Mam 2010;23:8-12.

10. Vermeer B, Van den Muijsenbergh ME. The attendance of migrant women at the national breast cancer screening in the Netherlands 1997-2008. Eur J Cancer Prev 2010;19:195-198.

11. Hartman E, van den Muijsenbergh ME, Haneveld RW. Breast cancer screening participation among Turks and Moroccans in the Netherlands: exploring reasons for nonattendance. Eur J Cancer Prev 2009;18:349-353.

12. Komenaka IK, Martinez ME, Pennington RE Jr, Hsu CH, Clare SE, Thompson PA, et al. Race and ethnicity and breast cancer outcomes in an underinsured population. J Natl Cancer Inst 2010;102:1178-87

13. Adams SA, Hebert JR, Bolick-Aldrich S, Daguise VG, Mosley CM, Modayil MV, et al. Breast cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. JSC Med Assoc 2006;102:231-239.

14. Ortega-Jacome GP, Koifman RJ, Rego-Monteiro GT, Koifman S. Environmental exposure and breast cancer among young women in Rio de Janeiro, Brazil. J Toxicol Environ Health A 2010;73:858-865.

15. Acea-Nebril B. Técnicas oncoplásticas para el manejo de tumores centrales de mama. Cir Esp 2009;85:14-19.

16. Hernanz-de La Fuente F, Gómez-Fleitas M, Martínez-García F. Mamoplastia de reducción en la cirugía del cáncer de mama. Cir Esp 2009;85:140-146.

17. Tebé C, Márquez-Calderón S, Ramón-Benítez J, Sánchez-Lanuza M, Fernández R, Aguado MJ, et al. Estado actual de la cirugía oncológica de mama en Andalucía y Cataluña. Cir Esp 2009;86:369-377.

18. Piñero-Madrona A, Polo-García L, Alonso-Romero JL, Salinas- Ramos J, Canteras-Jordana M, Sola-Pérez J, et al. Características inmunohistoquímicas del cáncer de mama: ¿hacia una nueva clasificación? Cir Esp 2008;84:138-145.

19. Acea-Nebril B. Cirugía oncoplástica conservadora en el cáncer de mama. Indicaciones y límites en su aplicación quirúrgica. Cir Esp 2005;78:12-18.

20. Merck B, Ramos-Rincón JM, Cansado P, Blas-Ballester J, Martínez-García F, Ramos-Boyero M, et al. Adecuación de las unidades de mama españolas a los criterios de EUSOMA. Cir Esp 2005;77:221-225.

21. Merck B, Cansado P, Fernández-Frías A, Rodríguez-Lescure A, Costa D, Lacueva FJ, et al. Aplicación de los criterios de EUSOMA en las unidades funcionales de mama de los países miembros de la Unión Europea. Cir Esp 2005;77:65-69.